Abstract | BACKGROUND: PATIENTS AND METHODS: We have reviewed the medical records of all patients with human immunodeficiency virus ( HIV) infection admitted to our section between January 1990 and December 1993 who were diagnosed with ADC, and we have compared them to those of a control group with regard to the interruption of ZDV at least 3 months before. Controls were selected from the remaining HIV-related admissions, matched by calendar year, CD4-cell count and previous HIV-disease stage. RESULTS: Thirty-nine cases and 39 controls were available for analysis; twenty-nine (74%) and 25 (64%) were male. The median age was similar for both groups: 30. Thirty-one patients (79%) in each group had a previous diagnosis of AIDS, six (15%) in each group had an AIDS-related complex and in two (5%) the ADC was the first complication of their HIV disease. The median CD4-cell counts were 79.6 and 79.4 x 10(6)/l. Twenty-three patients in each group had taken ZDV. Six of these from the ADC had withdrawn treatment, as compared to 2 from the control group (odds ratio [OR] 3.36; 95% confidence interval [CI]: 0.54-35.76). On the other hand, 16 patients with ADC were still on ZDV at the time of diagnosis, as compared to 21 controls (OR: 0.66; 95% CI: 0.22-1.60). CONCLUSION: In this case-control study, the interruption of treatment with ZDV was not found to be a risk factor for the development of ADC.
|
Authors | R Teira, E Uriarte, J Muñoz, J M Uterga, F Sádaba, Z Zubero, J M Santamaría |
Journal | Medicina clinica
(Med Clin (Barc))
Vol. 111
Issue 9
Pg. 325-8
(Sep 26 1998)
ISSN: 0025-7753 [Print] Spain |
Vernacular Title | Riesgo de desarrollo de demencia tras la interrupción de un tratamiento con zidovudina. |
PMID | 9810533
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Anti-HIV Agents
- Zidovudine
|
Topics |
- AIDS Dementia Complex
(etiology)
- Acquired Immunodeficiency Syndrome
(diagnosis, drug therapy)
- Adult
- Anti-HIV Agents
(administration & dosage, therapeutic use)
- CD4 Lymphocyte Count
- Case-Control Studies
- Confidence Intervals
- Female
- Humans
- Male
- Odds Ratio
- Risk Factors
- Time Factors
- Zidovudine
(administration & dosage, therapeutic use)
|